Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

The Act curbs US-China biotech collaborations, spurring opportunities for emerging markets in pharma supply chains.

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Shares of Medicus Pharma tumbled 39%, to $2.50, on the company's first day of trading Thursday. The biotechnology and life-sciences pharmaceutical company on Wednesday said it would sell 970,000 units ...

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

JB Pharma, Sun, Torrent ,Lupin, Abbott, Glenmark, Dr Reddy's Cipla, Zydus remained among Key pharma market growth drivers in ...

Shares of Inovio Pharmaceuticals ($INO) slipped nearly 2% on Thursday afternoon ahead of the company’s third-quarter results, ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The clinical stage biopharmaceutical company is developing inhaled drug delivery devices. Transpire Bio expands headquarters ...

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...